Neurodon Receives Funding from Elevate Ventures Through the 21st Century Research & Technology Fund
Neurodon Corporation, an Indiana-based pharmaceutical company, has received funding from Elevate Ventures, an Indianapolis-based venture capital company, through their SBIR/STTR Matching Program. This program is funded by the state of Indiana’s 21st Century Research & Technology Fund. Eligible Indiana-based companies that have received SBIR/STTR funding are eligible to apply for the program that provides 50% matching funds.
“We are excited to join the Elevate portfolio and are grateful for their support of Indiana companies,” said Dr. Russell Dahl, Neurodon’s CEO. “These non-dilutive funds from the state of Indiana will allow us to complete critical studies beyond the scope of our original STTR grant and position us favorably for Phase II STTR/SBIR funding from NIH. As an Indiana-based biotech company, we appreciate the resources of the Elevate ecosystem, and we look forward to a long relationship with their team.”
About Elevate Ventures
Elevate Ventures is committed to developing high-performing, high-growth, Indiana-based businesses. They accomplish this by providing investment capital to Indiana entrepreneurs and robust investment opportunities to funders, and by making value-added services available to entrepreneurs.
Neurodon is developing disease-modifying drugs for diabetes, neurodegeneration, and other life-threatening diseases. Neurodon deploys its proprietary ER stress-based technology platform to discover compounds that can reduce the cellular dysfunction that is the root cause of many diseases. For more information, visit www.neurodon.net.